{"hands_on_practices": [{"introduction": "The first step in diagnosing any form of liver injury is to establish a robust differential diagnosis based on clinical context and the pattern of enzyme elevation. This practice is designed to sharpen your ability to distinguish autoimmune hepatitis from its most common mimics by comparing and contrasting their hallmark laboratory and histological features. Mastering this comparative framework is fundamental to navigating complex cases of hepatocellular inflammation. [@problem_id:4330190]", "problem": "A patient presents with a hepatocellular pattern of liver injury, defined by predominant elevation of alanine aminotransferase ($ALT$) and aspartate aminotransferase ($AST$) relative to alkaline phosphatase ($ALP$). Starting from core definitions and well-tested facts in pathology—namely, that autoimmune injury is characterized by autoreactive lymphocytes and hypergammaglobulinemia, viral cytopathic injury is characterized by lobular apoptosis and specific serologic markers, copper metabolism disorders are characterized by impaired ceruloplasmin and hepatic copper accumulation, drug-induced liver injury (DILI) can manifest hypersensitivity features including eosinophils and cholestasis, and metabolic steatohepatitis arises from insulin resistance and lipotoxicity—select the option that correctly specifies one discriminating laboratory marker and one discriminating histologic feature for each of the following causes of hepatocellular inflammation: Autoimmune Hepatitis (AIH), Viral Hepatitis, Wilson Disease, Drug-Induced Liver Injury (DILI), and Nonalcoholic Steatohepatitis (NASH). Acronyms are defined at first mention: Immunoglobulin G (IgG), Antinuclear Antibody (ANA), Smooth Muscle Antibody (SMA), Liver Kidney Microsomal type 1 (LKM1), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) ribonucleic acid (RNA).\n\nChoose the single option that provides a scientifically consistent matrix of discriminators across all five entities.\n\nA. \n- AIH: Lab—elevated $IgG$ (for example, $> 1.1 \\times$ upper limit of normal) with positive autoantibodies (ANA, SMA, or LKM1), negative viral serologies; Histology—interface hepatitis (piecemeal necrosis) with portal plasma cell-rich infiltrates and hepatocyte rosette formation.\n- Viral hepatitis: Lab—positive HBsAg or detectable HCV RNA with marked $ALT/AST$ elevation; Histology—lobular disarray with spotty necrosis and acidophil bodies; portal lymphoid aggregates in HCV and ground-glass hepatocytes in hepatitis B.\n- Wilson disease: Lab—low ceruloplasmin (for example, $< 20$ mg/dL) and increased $24$-hour urinary copper (for example, $> 100$ µg/day), Kayser–Fleischer rings on slit-lamp; Histology—macrovesicular steatosis with glycogenated nuclei and positive copper-associated protein staining (rhodanine), occasional Mallory–Denk bodies.\n- DILI: Lab—recent exposure to an implicated medication with possible peripheral eosinophilia; Histology—eosinophil-rich portal inflammation with cholestasis and/or granulomas; pattern may vary by agent.\n- NASH: Lab—features of metabolic syndrome (obesity, type $2$ diabetes) with mildly elevated $ALT \\ge AST$; Histology—macrovesicular steatosis, ballooning degeneration, Mallory–Denk bodies, and perisinusoidal fibrosis accentuated in zone $3$.\n\nB.\n- AIH: Lab—low $IgG$ and negative autoantibodies; Histology—neutrophil-predominant lobular inflammation without interface activity.\n- Viral hepatitis: Lab—negative viral serologies; Histology—plasma cell-rich interface hepatitis with hepatocyte rosettes.\n- Wilson disease: Lab—normal ceruloplasmin with low urinary copper; Histology—florid bile duct lesions and granulomatous duct injury.\n- DILI: Lab—no drug exposure required; Histology—pure steatosis without inflammation or cholestasis.\n- NASH: Lab—markedly elevated $ALP$ with normal $ALT/AST$; Histology—confluent necrosis with acidophil bodies.\n\nC.\n- AIH: Lab—predominant cholestatic pattern with elevated $ALP$ and antimitochondrial antibody (AMA) positivity; Histology—granulomatous bile duct destruction and ductopenia.\n- Viral hepatitis: Lab—elevated $IgG$ and ANA positivity; Histology—absence of ground-glass hepatocytes; predominant plasma cells.\n- Wilson disease: Lab—high ceruloplasmin due to acute phase response; Histology—negative copper stain but positive iron deposition.\n- DILI: Lab—transient HBsAg positivity after exposure; Histology—panlobular necrosis indistinguishable from viral hepatitis.\n- NASH: Lab—obesity and type $2$ diabetes common; Histology—macrovesicular steatosis with ballooning and perisinusoidal fibrosis in zone $3$.\n\nD.\n- AIH: Lab—positive antimitochondrial antibody (AMA) and elevated $ALP$; Histology—ductopenia and bile duct destruction.\n- Viral hepatitis: Lab—positive HBsAg or HCV RNA; Histology—plasma cell-rich interface hepatitis with rosettes.\n- Wilson disease: Lab—low ceruloplasmin; Histology—macrovesicular steatosis with positive rhodanine copper staining.\n- DILI: Lab—recent drug exposure with eosinophilia; Histology—eosinophil-rich portal infiltrates with cholestasis or granulomas.\n- NASH: Lab—metabolic syndrome; Histology—macrovesicular steatosis, ballooning degeneration, and perisinusoidal fibrosis in zone $3$.", "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\nThe problem provides the following information:\n- A patient presents with a hepatocellular pattern of liver injury, defined by predominant elevation of alanine aminotransferase ($ALT$) and aspartate aminotransferase ($AST$) relative to alkaline phosphatase ($ALP$).\n- Core definitions and facts in pathology are given as premises:\n    - Autoimmune injury is characterized by autoreactive lymphocytes and hypergammaglobulinemia.\n    - Viral cytopathic injury is characterized by lobular apoptosis and specific serologic markers.\n    - Copper metabolism disorders are characterized by impaired ceruloplasmin and hepatic copper accumulation.\n    - Drug-induced liver injury (DILI) can manifest hypersensitivity features including eosinophils and cholestasis.\n    - Metabolic steatohepatitis arises from insulin resistance and lipotoxicity.\n- The task is to select the option that correctly specifies one discriminating laboratory marker and one discriminating histologic feature for each of five causes of hepatocellular inflammation: Autoimmune Hepatitis (AIH), Viral Hepatitis, Wilson Disease, Drug-Induced Liver Injury (DILI), and Nonalcoholic Steatohepatitis (NASH).\n- Acronyms are defined: Immunoglobulin G (IgG), Antinuclear Antibody (ANA), Smooth Muscle Antibody (SMA), Liver Kidney Microsomal type 1 (LKM1), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) ribonucleic acid (RNA).\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is based on established principles of hepatopathology and clinical medicine. The definitions provided for the etiological categories of liver disease are accurate and reflect standard medical knowledge. The premise of a differential diagnosis for a hepatocellular injury pattern is a fundamental and realistic clinical scenario.\n- **Well-Posed**: The question is structured as a multiple-choice question requiring the identification of a single option that presents a correct matrix of features for five distinct disease entities. This structure allows for a unique correct answer, provided one of the options is factually sound across all its components. The question is unambiguous.\n- **Objective**: The language is precise, technical, and free of subjective or opinion-based statements. It relies on standard and quantifiable medical terminology ($ALT$, $AST$, ceruloplasmin levels, autoantibody positivity, etc.).\n- **Completeness and Consistency**: The problem provides sufficient context and definitions to evaluate the options. The provided acronyms and pathological principles are standard and internally consistent. No essential information is missing, and there are no contradictions in the setup.\n- **Realism**: The scenario and the features being assessed (laboratory markers, histologic patterns) are entirely realistic and central to the practice of hepatology and pathology.\n- The problem does not exhibit any other flaws such as being non-formalizable, trivial, or unverifiable.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is a well-formulated, scientifically sound question that tests knowledge in a core area of pathology. I will now proceed with a detailed solution by evaluating each option.\n\n### Solution Derivation and Option-by-Option Analysis\nThe task is to find the option that correctly pairs discriminating laboratory and histologic features for five major causes of hepatocellular liver injury. I will analyze each option based on established principles of pathology, as outlined in the problem statement and confirmed by standard medical literature.\n\n**A. Evaluation of Option A:**\n- **Autoimmune Hepatitis (AIH):**\n    - Lab: \"elevated $IgG$ (for example, $> 1.1 \\times$ upper limit of normal) with positive autoantibodies (ANA, SMA, or LKM1), negative viral serologies\". This is the canonical laboratory profile for AIH, reflecting the hypergammaglobulinemia and presence of autoreactive antibodies mentioned in the problem's premises. Ruling out viral hepatitis is a mandatory step. This is correct.\n    - Histology: \"interface hepatitis (piecemeal necrosis) with portal plasma cell-rich infiltrates and hepatocyte rosette formation\". This is the classic pathognomonic triad for AIH. Interface hepatitis signifies the attack on hepatocytes at the portal-parenchymal junction. A plasma cell-rich infiltrate is the hallmark of the immune response in AIH. Rosette formation is a regenerative response to injury also characteristic of AIH. This is correct.\n- **Viral Hepatitis:**\n    - Lab: \"positive HBsAg or detectable HCV RNA with marked $ALT/AST$ elevation\". This correctly identifies the specific serologic markers for active hepatitis B and hepatitis C, respectively, along with the typical biochemical signature of acute or active viral hepatocyte injury. This is correct.\n    - Histology: \"lobular disarray with spotty necrosis and acidophil bodies; portal lymphoid aggregates in HCV and ground-glass hepatocytes in hepatitis B\". This accurately describes the general features of acute viral hepatitis (lobular inflammation and apoptosis, i.e., acidophil bodies), and correctly adds the specific distinguishing features for chronic HCV (lymphoid aggregates) and chronic HBV (ground-glass hepatocytes, which are cells filled with HBsAg). This is correct.\n- **Wilson Disease:**\n    - Lab: \"low ceruloplasmin (for example, $< 20$ mg/dL) and increased $24$-hour urinary copper (for example, $> 100$ µg/day), Kayser–Fleischer rings on slit-lamp\". These are the cornerstone diagnostic findings for Wilson disease, reflecting the core defect in copper metabolism. This is correct.\n    - Histology: \"macrovesicular steatosis with glycogenated nuclei and positive copper-associated protein staining (rhodanine), occasional Mallory–Denk bodies\". This correctly describes the variable histologic presentation, which can mimic steatohepatitis, and includes the definitive finding of excess copper demonstrated by a special stain like rhodanine. This is correct.\n- **Drug-Induced Liver Injury (DILI):**\n    - Lab: \"recent exposure to an implicated medication with possible peripheral eosinophilia\". The temporal link to a drug is essential for diagnosis, and eosinophilia is a classic (though not universal) sign of a drug hypersensitivity reaction, which is a common mechanism for DILI. This is correct.\n    - Histology: \"eosinophil-rich portal inflammation with cholestasis and/or granulomas; pattern may vary by agent\". This correctly highlights features that are highly suggestive of DILI (eosinophils, granulomas) while also acknowledging the critical fact that DILI is the \"great mimicker\" and its histologic pattern is highly variable. This is correct.\n- **Nonalcoholic Steatohepatitis (NASH):**\n    - Lab: \"features of metabolic syndrome (obesity, type $2$ diabetes) with mildly elevated $ALT \\ge AST$\". This accurately describes the clinical context and typical aminotransferase ratio in NASH, which helps distinguish it from alcoholic steatohepatitis (where typically $AST > ALT$). This is correct.\n    - Histology: \"macrovesicular steatosis, ballooning degeneration, Mallory–Denk bodies, and perisinusoidal fibrosis accentuated in zone $3$\". This is the textbook histologic definition of NASH, listing all the key components, including the characteristic location and pattern of early fibrosis (zone $3$, perisinusoidal or \"chicken-wire\" fibrosis). This is correct.\n\n**Verdict for A**: All five descriptions are scientifically accurate and represent the discriminating features for each disease. This option is **Correct**.\n\n**B. Evaluation of Option B:**\n- **AIH**: Lab: \"low $IgG$ and negative autoantibodies\". This is the opposite of the known characteristics of AIH. Histology: \"neutrophil-predominant lobular inflammation\" is incorrect; AIH is characterized by lymphoplasmacytic interface hepatitis. This is Incorrect.\n- **Viral hepatitis**: Lab: \"negative viral serologies\". This statement rules out viral hepatitis. This is Incorrect.\n- **Wilson disease**: Lab: \"normal ceruloplasmin with low urinary copper\". This is the opposite of the diagnostic findings in Wilson disease. This is Incorrect.\n- **DILI**: Lab: \"no drug exposure required\". This contradicts the definition of drug-induced injury. This is Incorrect.\n- **NASH**: Lab: \"markedly elevated $ALP$ with normal $ALT/AST$\". This describes a cholestatic, not a hepatocellular, pattern and is incorrect for NASH. This is Incorrect.\n\n**Verdict for B**: Every statement is factually incorrect. This option is **Incorrect**.\n\n**C. Evaluation of Option C:**\n- **AIH**: Lab: \"predominant cholestatic pattern with elevated $ALP$ and antimitochondrial antibody (AMA) positivity\". Histology: \"granulomatous bile duct destruction and ductopenia\". These are the defining features of Primary Biliary Cholangitis (PBC), not AIH. This is Incorrect.\n- **Viral hepatitis**: Lab: \"elevated $IgG$ and ANA positivity\". These are features of AIH, not viral hepatitis. This is Incorrect.\n- **Wilson disease**: Lab: \"high ceruloplasmin\". Low ceruloplasmin is the key finding. Histology: \"positive iron deposition\". This describes hemochromatosis, not Wilson disease (a disorder of copper). This is Incorrect.\n- **DILI**: Lab: \"transient HBsAg positivity after exposure\". This is biologically impossible; drug exposure cannot cause the production of a viral antigen. This is Incorrect.\n- **NASH**: The description is correct. However, since the other four entries are flawed, the entire option fails.\n\n**Verdict for C**: The option contains multiple, fundamental errors, confusing the features of distinct diseases. This option is **Incorrect**.\n\n**D. Evaluation of Option D:**\n- **AIH**: Lab: \"positive antimitochondrial antibody (AMA) and elevated $ALP$\". Histology: \"ductopenia and bile duct destruction\". As in option C, this describes Primary Biliary Cholangitis (PBC). This is Incorrect.\n- **Viral hepatitis**: Histology: \"plasma cell-rich interface hepatitis with rosettes\". This is the classic description of AIH, not viral hepatitis. While chronic viral hepatitis can have interface activity, it is typically not as plasma cell-rich, and rosettes are not a characteristic feature. This is Incorrect.\n- **Wilson disease**, **DILI**, **NASH**: The descriptions for these three entities are correct. However, the question demands an option that is correct across *all five* entities. The gross mischaracterization of AIH and viral hepatitis renders the entire option invalid.\n\n**Verdict for D**: The option contains critical errors in its descriptions of AIH and viral hepatitis, making it an inconsistent and incorrect matrix. This option is **Incorrect**.\n\n### Final Conclusion\nOnly option A provides a fully accurate and consistent set of discriminating laboratory and histologic features for all five diseases in the differential diagnosis of hepatocellular injury. The other options contain numerous factual errors and misattributions of features between different diseases.", "answer": "$$\\boxed{A}$$", "id": "4330190"}, {"introduction": "Once autoimmune hepatitis is suspected, diagnosis is formalized using a standardized scoring system that integrates multiple lines of evidence. This exercise provides hands-on practice in applying the simplified International Autoimmune Hepatitis Group (IAIHG) criteria to a clinical case. By systematically assigning points for autoantibodies, $IgG$ levels, histology, and the absence of viral markers, you will learn to translate a complex clinical picture into a definitive diagnostic score. [@problem_id:4330211]", "problem": "A 34-year-old individual presents with chronically elevated serum aminotransferases, fatigue, and arthralgias. Serologic testing reveals antinuclear antibody (ANA) at a titer of $1:160$. Serum immunoglobulin G (IgG) is elevated to $1.8\\times$ the upper limit of normal (ULN). Serologies for viral hepatitis, including hepatitis B surface antigen and hepatitis C virus antibody, are negative. Liver biopsy demonstrates interface hepatitis with a dense lymphoplasmacytic infiltrate and hepatocyte rosette formation, described by the pathologist as typical for autoimmune hepatitis. Using the simplified International Autoimmune Hepatitis Group (IAIHG) criteria, compute the total diagnostic score and determine whether this corresponds to probable or definite autoimmune hepatitis. Report only the total simplified score as your final numeric answer. No rounding is necessary, and no units are required.", "solution": "The problem statement is a valid clinical scenario requiring the application of a standardized diagnostic scoring system. All necessary data are provided, the terminology is precise, and the objective is clear. The problem is scientifically grounded in the field of hepatology and is well-posed.\n\nThe task is to compute the total diagnostic score for autoimmune hepatitis (AIH) using the simplified International Autoimmune Hepatitis Group (IAIHG) criteria. This scoring system is based on four parameters: autoantibodies, serum immunoglobulin G (IgG) level, liver histology, and the absence of viral hepatitis. We will evaluate each component based on the data provided in the problem statement.\n\n1.  **Autoantibodies:** The patient's antinuclear antibody (ANA) titer is given as $1:160$. According to the simplified IAIHG criteria, an ANA titer of $\\ge 1:40$ scores $1$ point, and a titer of $\\ge 1:80$ scores $2$ points. Since $160 \\ge 80$, this component contributes $2$ points to the total score.\n\n2.  **Serum Immunoglobulin G (IgG):** The patient's serum IgG level is elevated to $1.8 \\times$ the upper limit of normal (ULN). The scoring criteria assign $1$ point for an IgG level greater than the ULN and $2$ points for an IgG level greater than $1.10 \\times$ the ULN. Since $1.8 > 1.10$, this component contributes $2$ points to the score.\n\n3.  **Liver Histology:** The liver biopsy findings are described as \"interface hepatitis with a dense lymphoplasmacytic infiltrate and hepatocyte rosette formation,\" which the pathologist deemed \"typical for autoimmune hepatitis.\" The simplified criteria award $1$ point for histology \"compatible with AIH\" and $2$ points for histology \"typical for AIH.\" The description provided corresponds to the \"typical\" features. Therefore, this component contributes $2$ points.\n\n4.  **Absence of Viral Hepatitis:** The problem states that serologies for viral hepatitis, specifically hepatitis B surface antigen and hepatitis C virus antibody, are negative. The presence of this finding (i.e., the absence of active viral hepatitis) contributes $2$ points to the score.\n\nThe total simplified IAIHG score is the sum of the points from these four categories.\n\nTotal Score = (Autoantibody score) + (IgG score) + (Histology score) + (Absence of viral hepatitis score)\n\n$$\n\\text{Total Score} = 2 + 2 + 2 + 2 = 8\n$$\n\nThe interpretation of the final score is as follows:\n- A score of $\\ge 6$ indicates \"probable AIH.\"\n- A score of $\\ge 7$ indicates \"definite AIH.\"\n\nWith a total score of $8$, the patient's presentation corresponds to a diagnosis of definite autoimmune hepatitis. The problem, however, asks for the total simplified score as the final numeric answer.", "answer": "$$\\boxed{8}$$", "id": "4330211"}, {"introduction": "Effective management of autoimmune hepatitis requires objective monitoring of the response to immunosuppressive therapy. This practice demonstrates how pathologists quantify changes in liver inflammation using the Ishak Histologic Activity Index (HAI). You will translate descriptive biopsy findings into numerical scores for key features like interface hepatitis and lobular necrosis, thereby calculating a total activity score that serves as a powerful biomarker for tracking treatment efficacy. [@problem_id:4330203]", "problem": "A patient with autoimmune hepatitis begins standard immunosuppressive therapy and undergoes liver biopsy at baseline and after $12$ weeks. You are provided histologic descriptors and are asked to construct the Ishak Histologic Activity Index (HAI) for each time point and quantify change as a marker of treatment response. Use the following widely accepted operational definitions for the Ishak HAI components, which map descriptive histologic features to ordinal scores:\n\nPeriportal or interface hepatitis (piecemeal necrosis), score $A \\in \\{0,1,2,3,4\\}$:\n- $0$: none.\n- $1$: mild, focal, in few portal tracts.\n- $2$: mild to moderate, focal, in many portal tracts.\n- $3$: moderate, continuous interface activity around less than half of portal tracts.\n- $4$: severe, continuous interface activity around at least half of portal tracts (i.e., $\\geq \\tfrac{1}{2}$ of portal tracts).\n\nConfluent necrosis, score $B \\in \\{0,1,2,3,4,5,6\\}$:\n- $0$: none.\n- $1$: focal confluent necrosis.\n- $2$: zone $3$ necrosis in some areas.\n- $3$: zone $3$ necrosis in most areas.\n- $4$: zone $3$ necrosis with occasional bridging.\n- $5$: marked bridging necrosis.\n- $6$: multiacinar necrosis.\n\nFocal lobular necroinflammation (spotty lytic necrosis, apoptosis and focal inflammation), score $C \\in \\{0,1,2,3,4\\}$, based on average foci per $10\\times$ field in areas of greatest activity:\n- $0$: none.\n- $1$: less than $1$ focus per field on average.\n- $2$: from $1$ to $4$ foci per field on average.\n- $3$: from $5$ to $10$ foci per field on average.\n- $4$: more than $10$ foci per field on average.\n\nPortal inflammation, score $D \\in \\{0,1,2,3,4\\}$:\n- $0$: none.\n- $1$: mild in some or all portal areas.\n- $2$: moderate in all portal areas.\n- $3$: marked in all portal areas.\n- $4$: marked with expansion beyond the limiting plate into periportal parenchyma.\n\nThe Ishak HAI total activity score is defined as the sum of the component scores $A$, $B$, $C$, and $D$.\n\nBaseline biopsy descriptors:\n- Sections contain $12$ portal tracts. Interface activity forms continuous circumferential arcs around $8$ of $12$ portal tracts, with only focal activity in the remainder.\n- Confluent necrosis consists of frequent portal–portal and central–central bridges without multiacinar collapse.\n- In lobules, there are on average $6$ foci of spotty necroinflammation per $10\\times$ field in the most active areas.\n- Portal tracts show marked lymphoplasmacytic inflammation with expansion into periportal parenchyma.\n\nWeek $12$ biopsy descriptors:\n- Interface hepatitis is focal and limited to a few portal tracts; there are no continuous arcs.\n- Confluent necrosis is absent.\n- In lobules, there are on average $1$ to $2$ foci of spotty necroinflammation per $10\\times$ field in the most active areas.\n- Portal tracts show mild inflammation.\n\nCompute the Ishak HAI total score at baseline and at week $12$, then compute the change in total activity score defined as baseline minus week $12$. Report only this change as your final answer. No rounding is necessary, and no units are required.", "solution": "The user has asked me to find the change in the Ishak Histologic Activity Index (HAI) score for a patient with autoimmune hepatitis between a baseline biopsy and a biopsy at week $12$ of treatment.\n\nFirst, I will validate the problem statement.\n\n### Step 1: Extract Givens\n- Ishak HAI component scores are defined as follows:\n    - Periportal or interface hepatitis (score $A \\in \\{0,1,2,3,4\\}$):\n        - $0$: none.\n        - $1$: mild, focal, in few portal tracts.\n        - $2$: mild to moderate, focal, in many portal tracts.\n        - $3$: moderate, continuous interface activity around less than half of portal tracts.\n        - $4$: severe, continuous interface activity around at least half of portal tracts (i.e., $\\geq \\frac{1}{2}$ of portal tracts).\n    - Confluent necrosis (score $B \\in \\{0,1,2,3,4,5,6\\}$):\n        - $0$: none.\n        - $1$: focal confluent necrosis.\n        - $2$: zone $3$ necrosis in some areas.\n        - $3$: zone $3$ necrosis in most areas.\n        - $4$: zone $3$ necrosis with occasional bridging.\n        - $5$: marked bridging necrosis.\n        - $6$: multiacinar necrosis.\n    - Focal lobular necroinflammation (score $C \\in \\{0,1,2,3,4\\}$):\n        - $0$: none.\n        - $1$: less than $1$ focus per field on average.\n        - $2$: from $1$ to $4$ foci per field on average.\n        - $3$: from $5$ to $10$ foci per field on average.\n        - $4$: more than $10$ foci per field on average.\n    - Portal inflammation (score $D \\in \\{0,1,2,3,4\\}$):\n        - $0$: none.\n        - $1$: mild in some or all portal areas.\n        - $2$: moderate in all portal areas.\n        - $3$: marked in all portal areas.\n        - $4$: marked with expansion beyond the limiting plate into periportal parenchyma.\n- The Ishak HAI total activity score is the sum of the component scores: $HAI = A + B + C + D$.\n- Baseline biopsy descriptors:\n    - Sections contain $12$ portal tracts. Interface activity forms continuous circumferential arcs around $8$ of $12$ portal tracts.\n    - Confluent necrosis consists of frequent portal–portal and central–central bridges without multiacinar collapse.\n    - On average $6$ foci of spotty necroinflammation per $10\\times$ field.\n    - Portal tracts show marked lymphoplasmacytic inflammation with expansion into periportal parenchyma.\n- Week $12$ biopsy descriptors:\n    - Interface hepatitis is focal and limited to a few portal tracts.\n    - Confluent necrosis is absent.\n    - On average $1$ to $2$ foci of spotty necroinflammation per $10\\times$ field.\n    - Portal tracts show mild inflammation.\n- The task is to compute the change in total activity score, defined as $HAI_{baseline} - HAI_{week\\,12}$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, as it uses the real and established Ishak Histologic Activity Index, a standard tool in liver pathology for grading chronic hepatitis. The histologic descriptors are standard terminology. The problem is well-posed, providing a clear set of rules (the scoring system) and the necessary data (the biopsy descriptions) to apply them. The language is objective and free of ambiguity. The problem is self-contained and logically consistent. Therefore, the problem is deemed valid.\n\n### Step 3: Verdict and Action\nThe problem is valid. I will now proceed with the solution.\n\nThe solution requires calculating the total HAI score at baseline and at week $12$, then finding the difference. The total score, $HAI$, is the sum of four component scores: $A$, $B$, $C$, and $D$.\n\n**Calculation for Baseline Biopsy ($HAI_{baseline}$):**\n\n1.  **Periportal hepatitis (Score $A_{baseline}$):** The description states, \"Interface activity forms continuous circumferential arcs around $8$ of $12$ portal tracts.\" The fraction of involved portal tracts is $\\frac{8}{12} = \\frac{2}{3}$. The scoring criterion for $A=4$ is \"continuous interface activity around at least half of portal tracts ($\\geq \\frac{1}{2}$ of portal tracts)\". Since $\\frac{2}{3} \\geq \\frac{1}{2}$, this condition is met.\n    Therefore, $A_{baseline} = 4$.\n\n2.  **Confluent necrosis (Score $B_{baseline}$):** The description is, \"Confluent necrosis consists of frequent portal–portal and central–central bridges without multiacinar collapse.\" This corresponds to \"marked bridging necrosis\", which is the definition for a score of $5$. The mention of \"without multiacinar collapse\" explicitly excludes a score of $6$.\n    Therefore, $B_{baseline} = 5$.\n\n3.  **Focal lobular necroinflammation (Score $C_{baseline}$):** The description states, \"there are on average $6$ foci of spotty necroinflammation per $10\\times$ field\". The scoring criterion for $C=3$ is \"from $5$ to $10$ foci per field on average\". The value $6$ falls within this range.\n    Therefore, $C_{baseline} = 3$.\n\n4.  **Portal inflammation (Score $D_{baseline}$):** The description is, \"Portal tracts show marked lymphoplasmacytic inflammation with expansion into periportal parenchyma.\" This directly matches the definition for a score of $4$: \"marked with expansion beyond the limiting plate into periportal parenchyma.\"\n    Therefore, $D_{baseline} = 4$.\n\nThe total baseline HAI score is the sum of these components:\n$$HAI_{baseline} = A_{baseline} + B_{baseline} + C_{baseline} + D_{baseline} = 4 + 5 + 3 + 4 = 16$$\n\n**Calculation for Week $12$ Biopsy ($HAI_{week\\,12}$):**\n\n1.  **Periportal hepatitis (Score $A_{week\\,12}$):** The description is, \"Interface hepatitis is focal and limited to a few portal tracts\". This directly matches the definition for a score of $1$: \"mild, focal, in few portal tracts.\"\n    Therefore, $A_{week\\,12} = 1$.\n\n2.  **Confluent necrosis (Score $B_{week\\,12}$):** The description is, \"Confluent necrosis is absent.\" This corresponds to the definition for a score of $0$: \"none\".\n    Therefore, $B_{week\\,12} = 0$.\n\n3.  **Focal lobular necroinflammation (Score $C_{week\\,12}$):** The description states, \"there are on average $1$ to $2$ foci of spotty necroinflammation per $10\\times$ field\". This range is contained within the scoring criterion for $C=2$: \"from $1$ to $4$ foci per field on average.\"\n    Therefore, $C_{week\\,12} = 2$.\n\n4.  **Portal inflammation (Score $D_{week\\,12}$):** The description is, \"Portal tracts show mild inflammation.\" This matches the definition for a score of $1$: \"mild in some or all portal areas.\"\n    Therefore, $D_{week\\,12} = 1$.\n\nThe total week $12$ HAI score is the sum of these components:\n$$HAI_{week\\,12} = A_{week\\,12} + B_{week\\,12} + C_{week\\,12} + D_{week\\,12} = 1 + 0 + 2 + 1 = 4$$\n\n**Calculation of the Change in Score:**\n\nThe problem requests the change in total activity score, defined as the baseline score minus the week $12$ score.\n$$ \\Delta HAI = HAI_{baseline} - HAI_{week\\,12} $$\n$$ \\Delta HAI = 16 - 4 = 12 $$\nThe change in the Ishak HAI total activity score is $12$.", "answer": "$$\\boxed{12}$$", "id": "4330203"}]}